Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib
- 31 July 2022
- journal article
- letter
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15724
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A case of lichen amyloidosis associated with atopic dermatitis successfully treated with dupilumab: A case report and literature reviewDermatologic Therapy, 2021
- Interleukin-31 as a Clinical Target for Pruritus TreatmentFrontiers in Medicine, 2021
- Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementAnnals of the Rheumatic Diseases, 2021
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyJournal of the American Academy of Dermatology, 2019
- Primary Localized Cutaneous Amyloidosis: A Systematic Treatment ReviewAmerican Journal of Clinical Dermatology, 2017
- Pathophysiology of pruritus in primary localized cutaneous amyloidosisBritish Journal of Dermatology, 2016
- Cutaneous Amyloidosis: A Concept ReviewThe American Journal of Dermatopathology, 2012
- Primary localized cutaneous nodular amyloidosis that appeared in a patient with severe atopic dermatitisThe Journal of Dermatology, 2011
- Diagnostic Features of Atopic DermatitisActa Dermato-Venereologica, 1980